Home / Resources / Generics Bulletin Top 50 Ranking for 2024
Generics Bulletin Top 50 Ranking for 2024

This eBook compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

Generics Bulletin Top 50 Ranking for 2024
Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Thank you.




Your download should open in a new window. You can also manually download by clicking the button below.
Related products
New medicine product news and analysis are included in Citeline's Generics Bulletin offerings.
Generics Bulletin
Unrivaled news and analysis of the global generics, biosimilars and value-added medicines industries
Expert interview with a biopharma leader for insights and strategy.
In Vivo
Interviews, analysis and critical insights for life science decision-makers
Expert analyst presenting data insights on a projected screen.
Biomedtracker
Real-time tracking and analysis of the drug development pipeline

Related resources

3D model of a RNA strand.
JUL 30, 2024
Report
Commercial

Q2 2024 Gene, Cell, + RNA Therapy Landscape Report

In this report, by Citeline and the American Society of Gene & Cell Therapy (ASGCT), new approvals in Q2 2024 were focused on the RNA landscape.

Stacks of coins arranged in ascending order with a white arrow and line graph overlay indicating growth
JUN 11, 2024
eBook
Commercial

Billion Dollar Blueprint: The Journey to Blockbuster Status

The industry’s top-selling drugs generate billions in revenues each year. Scrip analyzed data on nearly 200 blockbuster drugs, in search of the secret formula for creating the next pharmaceutical behemoth.

Citeline professional presenting the Q3 2024 Outlook Report provided by Biomedtracker.
JUL 08, 2024
Report
Commercial

Q3 2024 Outlook Report

In this report, we cover catalysts from 24 drugs, devices, diagnostics, and deals expected to occur in Q3 2024.

View all